Adc Therapeutics Sa Stock Filter Stocks by Fundamentals
| ADCT Stock | USD 2.26 0.04 1.80% |
ADC Therapeutics SA fundamentals help investors to digest information that contributes to ADC Therapeutics' financial success or failures. It also enables traders to predict the movement of ADC Stock. The fundamental analysis module provides a way to measure ADC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADC Therapeutics stock.
ADC | Shares Owned by Institutions |
ADC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.0B | 2.1B | 1.6B | 300.1M | 135.6M | 128.9M | |
| Enterprise Value | 1.9B | 1.7B | 1.2B | 91.0M | (18.6M) | (17.6M) |
ADC Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ADC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ADC Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
ADC Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in ADC Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ADC Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ADC Therapeutics' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 953.2 K | Vantage Consulting Group Inc. | 2024-06-30 | 850.7 K | Millennium Management Llc | 2024-06-30 | 816.5 K | Blue Owl Capital Holdings Lp | 2024-09-30 | 733.6 K | Vanguard Group Inc | 2024-09-30 | 539.4 K | Northern Trust Corp | 2024-09-30 | 481 K | Gcm Grosvenor Holdings, Llc | 2024-09-30 | 410.9 K | D. E. Shaw & Co Lp | 2024-09-30 | 284.2 K | Two Sigma Investments Llc | 2024-09-30 | 245.3 K | Redmile Group, Llc | 2024-09-30 | 15.7 M | Prosight Management, Lp | 2024-06-30 | 9.6 M |
ADC Fundamentals
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (3.00) % | ||||
| Operating Margin | (1.93) % | ||||
| Current Valuation | 68.8 M | ||||
| Shares Outstanding | 96.69 M | ||||
| Shares Owned By Insiders | 21.02 % | ||||
| Shares Owned By Institutions | 61.00 % | ||||
| Number Of Shares Shorted | 3.16 M | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 3.09 X | ||||
| Revenue | 69.56 M | ||||
| Gross Profit | 35.1 M | ||||
| EBITDA | (146.76 M) | ||||
| Net Income | (240.05 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 124.38 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (1.78) X | ||||
| Cash Flow From Operations | (118.69 M) | ||||
| Short Ratio | 8.61 X | ||||
| Earnings Per Share | (2.39) X | ||||
| Price To Earnings To Growth | 0.74 X | ||||
| Target Price | 8.4 | ||||
| Number Of Employees | 273 | ||||
| Beta | 1.6 | ||||
| Market Capitalization | 218.52 M | ||||
| Total Asset | 354.78 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 268.62 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
| Net Asset | 354.78 M |
About ADC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.